PO.ET04.01 · 实验与分子治疗

分泌IL-7的Salmonella与PD-L1阻断协同诱导持久的抗肿瘤免疫记忆

IL-7-secreting Salmonella synergizes with PD-L1 blockade to induce durable antitumor immune memory

海报缩略图:分泌IL-7的Salmonella与PD-L1阻断协同诱导持久的抗肿瘤免疫记忆
编号 271 展板 14 时间 4/19 02:00–05:00 区域 Section 12 主讲 Minju Han, BS
分会场 Gene and Vector-Based Therapy
查看 PDF 下载 PDF 🔒 查看 / 下载完整 PDF 需登录并开通下载套餐 · 查看套餐 / 开通 AACR 官方页面

作者与单位 Authors & Affiliations

Minju Han

Chungnam National University, Yuseong, Daejeon, Korea, Republic of

摘要 Abstract

中文摘要
背景:白细胞介素-7(IL-7)是维持T细胞存活和稳态并诱导抗肿瘤免疫应答的关键细胞因子。本研究考察了经基因工程改造以分泌IL-7的减毒Salmonella通过激活免疫细胞应答对抗癌症的抗肿瘤效应。 方法:使用小鼠结直肠癌细胞系CT26和S. typhimurium。S. typhimurium基于阿拉伯糖诱导系统经工程改造以分泌IL-7。在体外和体内考察了工程化Salmonella单独使用以及与抗PD-L1治疗联合使用的抗肿瘤效应。进行流式细胞术以分析肿瘤和脾脏中的免疫细胞群体,以阐明潜在机制。 结果:经基因工程改造的Salmonella在阿拉伯糖诱导下分泌IL-7而不影响其生长。通过ELISA确认了对阿拉伯糖响应的IL-7分泌。在体内实验中,阿拉伯糖诱导组相比未诱导组表现出增强的抗肿瘤效应和改善的生存期,在Salmonella注射后五天内观察到体重恢复。TUNEL分析显示阿拉伯糖诱导后肿瘤组织中凋亡增加,同时Ki67表达显著降低。在诱导后第3天和第7天,流式细胞术显示T细胞群体增加。通过颗粒酶B、穿孔素和IFN-γ水平升高确认了细胞毒性T细胞的激活。分泌IL-7的Salmonella与抗PD-L1抗体的联合给药相比单独分泌IL-7的Salmonella带来了显著更强的肿瘤抑制。值得注意的是,在阿拉伯糖诱导组中,5只小鼠中有4只观察到完全肿瘤消退。60天后在对侧腹部重新攻击肿瘤细胞时,未检测到肿瘤复发,表明建立了长期抗肿瘤免疫。随后对脾细胞的流式细胞术分析确认了记忆T细胞群体的增加,支持IL-7分泌后持久免疫记忆的形成。生物分布分析显示Salmonella随时间从其他器官被清除,主要在肿瘤组织中蓄积。肝肾功能的生化分析显示阿拉伯糖处理组无异常。通过生物分布研究和H&E染色确认了该Salmonella菌株的生物安全性。 结论:分泌IL-7的Salmonella通过诱导T细胞介导的免疫应答增强抗肿瘤活性,尤其在与抗PD-L1抗体联合使用时,显示出作为实体瘤免疫治疗策略的潜力。仍需进一步研究以评估其在各种肿瘤模型中的疗效、长期安全性以及与其他免疫检查点抑制剂联合的潜力。
查看英文原文 English abstract
Background: Interleukin-7 (IL-7) is a key cytokine that maintains the survival and homeostasis of T cells and induces antitumor immune responses. This study investigated the antitumor effects of attenuated Salmonella genetically engineered to secrete IL-7 against cancer by activating immune cell responses. Methods: Mouse colorectal cancer cell line CT26 and S. typhimurium were used. The S. typhimurium was engineered to secrete IL-7 based on an arabinose induction system. The anti-tumor effect of the engineered Salmonella was examined in vitro and in vivo , both alone and in combination with anti-PD-L1 treatment. Flow cytometry was performed to analyze immune cell populations in tumors and spleens to elucidate the underlying mechanisms. Results: The genetically engineered Salmonella secreted IL-7 upon arabinose induction without affecting its growth. IL-7 secretion in response to arabinose was confirmed via ELISA. In in vivo experiments, the arabinose-induced group exhibited enhanced antitumor effects and improved survival compared to the non-induced group, with body weight recovery observed within five days post- Salmonella injection. TUNEL analysis showed increased apoptosis in tumor tissues following arabinose induction, along with a significant reduction in Ki67 expression. On days 3 and 7 post-induction, flow cytometry revealed an increased T cell population. The activation of cytotoxic T cells was confirmed by elevated levels of granzyme B, perforin, and IFN-gamma. Co-administration of IL-7-secreting Salmonella with anti-PD-L1 antibody resulted in significantly greater tumor suppression compared to Salmonella secreting IL-7 alone. Notably, in the arabinose-induced group, complete tumor regression was observed in 4 out of 5 mice. When tumor cells were re-challenged on the opposite flank 60 days later, no tumor recurrence was detected, indicating the establishment of long-term antitumor immunity. Subsequent flow cytometric analysis of splenocytes confirmed an increased population of memory T cells, supporting the development of durable immune memory following IL-7 secretion. Biodistribution analysis showed that Salmonella was cleared from other organs over time, with predominant accumulation in tumor tissue. Biochemical analyses of liver and kidney function revealed no abnormalities in the arabinose-treated group. The biological safety of the Salmonella strain was confirmed through biodistribution studies and H&E staining. Conclusion: The Salmonella secreting IL-7 enhances antitumor activity by inducing T cell-mediated immune responses, particularly showing potential as an immunotherapy strategy for solid tumors when combined with anti-PD-L1 antibodies. Further research is needed to evaluate its efficacy in various tumor models, long-term safety, and the potential for combination with other immune checkpoint inhibitors.
利益披露 Disclosure
M. Han, None.

← 返回 AACR 2026 检索